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Introduction
A number of single nucleotide polymorphisms (SNP) of dif-
ferent genes have been associated with disease predisposi-
tion.1-4 While the potential effects of gene polymorphisms are
widely acknowledged, most studies investigating the impact
of individual SNPs on prognosis in chronic lymphocytic
leukemia (CLL) have been controversial.5-11 None of the allelic
variants described so far contribute to relevant current clinical
risk models in CLL.12,13 
Sample sizes of studies to detect associations between SNP
markers and clinical end points should be reasonably large,
taking into account the very large number of candidate SNPs.
In the absence of large studies, individual patient data (IPD)-
based meta-analyses can provide a reliable assessment of pos-
sibly prognostic SNP markers. However, few IPD-based
meta-analyses on SNP data have been performed so far.
A number of years ago, a single nucleotide polymorphism
in the MDM2 promotor region (IVS1+309) was discovered
and shown to soothe the p53 pathway by influencing MDM2
transcript and protein levels.14,15 Patients with the Li-Fraumeni
syndrome develop cancers a decade earlier, when carrying
the G/G allele of MDM2SNP309. These important findings have
led to the investigation of the role of the MDM2 polymor-
phism in a variety of cancers with conflicting results. A com-
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A number of single nucleotide polymorphisms have been associated with disease predisposition in chronic lympho-
cytic leukemia. A single nucleotide polymorphism in the MDM2 promotor region, MDM2SNP309, was shown to
soothe the p53 pathway. In the current study, we aimed to clarify the effect of the MDM2SNP309 on chronic lym-
phocytic leukemia characteristics and outcome. We performed a meta-analysis of data from 2598 individual patients
from 10 different cohorts. Patients' data and genetic analysis for MDM2SNP309 genotype, immunoglobulin heavy
chain variable region mutation status and fluorescence in situ hybridization results were collected. There were no dif-
ferences in overall survival based on the polymorphism (log rank test, stratified by study cohort; P=0.76; GG geno-
type: cohort-adjusted median overall survival of 151 months; TG: 153 months; TT: 149 months). In a multivariable
Cox proportional hazards regression analysis, advanced age, male sex and unmutated immunoglobulin heavy chain
variable region genes were associated with inferior survival, but not the MDM2 genotype. The MDM2SNP309 is
unlikely to influence disease characteristics and prognosis in chronic lymphocytic leukemia. Studies investigating the
impact of individual single nucleotide polymorphisms on prognosis are often controversial. This may be due to selec-
tion bias and small sample size. A meta-analysis based on individual patient data provides a reasonable strategy for
prognostic factor analyses in the case of small individual studies. Individual patient data-based meta-analysis can,
therefore, be a powerful tool to assess genetic risk factors in the absence of large studies. 
ABSTRACT
bined meta-analysis of breast, colorectal and lung cancers
found no effect of the SNP on predisposition in colorectal
and breast cancer, but showed a small but significant pre-
disposition to lung cancer.16 Most positive findings on the
MDM2SNP309 genotype were related to disease onset rather
than outcome.16 The exceptionally well documented func-
tional consequences of the MDM2SNP309 and the important
prognostic role of p53,17,18 as well as the particularly strik-
ing effects of the SNP in CLL in one study, has led to the
study of the MDM2SNP309 in many centers, providing con-
flicting results.5,6,9-11,19 
In the current study, we aimed to clarify the prognostic
value of MDM2SNP309, as well as the correlation between
this SNP and the characteristics of CLL, by using an IPD-
based meta-analysis.20 To this end, we have collected data
from 10 European centers contributing pre-determined
clinical and genetic information on their patient cohorts.
The combined data set is the largest cohort analyzed for
the prognostic impact of genetic risk groups in CLL and
thus constitutes a powerful data set to approach prognos-
tic models in this disease.
Methods
Cohorts
This meta-analysis includes individual patient data from 10
cohorts (n=2598) (Figure 1). The cohorts have, in part, been pub-
lished previously.5-9,11 Two data sets were unavailable either
because of regulatory issues21 or due to the decision of the inves-
tigator.22,23 Tables 1 and 2 show the characteristics of the meta-
analysis data set. Details are provided in the Online Supplementary
Appendix.
Statistical analysis
Meta-analyses are applied to combine the results of related
studies to produce an overall effect estimate. The large majority
of meta-analyses use summary statistics supplied by the trial
investigators or extracted from trial reports. Trial-level results are
then combined to produce an overall effect estimate. A more
powerful and less biased approach collects individual patient data
(IPD) directly from the researchers responsible for each trial. Use
of IPD has several advantages over the aggregate data approach,
including standardization of statistical analyses, the assessment
of potential causes of heterogeneity, and the investigation of
interactions and non-linear effects.  IPD-based meta-analysis is
especially useful when time-to-event data are of interest. For sur-
vival analysis, the approach uses individual survival times and
takes account of censoring. This provides a more powerful and
flexible approach compared to the use of aggregate data since
power is lost if time is ignored.
In our study, we apply an approach based on a single propor-
tional hazards regression model stratified by trial. In order to
incorporate random effects, a mixed-effect regression model is
used. The primary end point of the IPD-based meta-analysis
study presented here was overall survival (OS), and the second
was time to first treatment (TFT). OS was defined as the time
from diagnosis to death (event) or last follow up. TFT was
defined as the time interval between the date of diagnosis and
date of first CLL-specific treatment or death. TFT was censored
at last treatment-free follow-up date. The log rank test, stratified
by center, was used to compare survival curves with respect to
MDM2SNP309 genotypes. For multivariable survival analysis, the
proportional hazards regression model of Cox was applied
including patients' sex, age, IGVH gene mutation status and FISH
results. For the MDM2SNP309, an additive genetic model was used
with values 0, 1, and 2, indicating the number of copies of the
variant G allele for each patient. A stratified approach was used,
allowing each center to have a different base-line hazard. We
applied mixed effects Cox proportional hazards models with a
random center effect to consider between-center heterogeneity.24
Univariable survival distributions according to genotype are pro-
vided as direct adjusted survival curves, adjusted for cohort.25
Forest plots were used to present results for individual centers
and the combined analysis. Cochran’s Q was applied to test het-
erogeneity, whereas the I2 index was used to quantify the degree
of heterogeneity between cohorts. Bias and systematic hetero-
geneity was checked by contour-enhanced funnel plots, where
the standard error is plotted against the log hazard ratio
estimate.26 The contour enhanced funnel plots also indicate
regions of statistical significance at levels of 0.01, 0.05 and 0.1,
testing the null hypotheses that log hazard ratios are equal to
zero. 
Results
A total of 2598 patients were included in this study,
gathered from 10 different single-center series from
Europe. The comparison of the base-line characteristics of
different cohorts is shown in Table 1, while time-to-event
data (survival time, time to first treatment) are shown in
Table 2. Median overall survival from diagnosis ranged
from a median of 104 months to 301 months. Not surpris-
ingly, there was a difference in outcome of the cohorts
with respect to overall survival and time to first treatment
reflecting the patient cohort differences and the respective
referral patterns. As expected, the most important known
genetic risk factors (17p-, 11q-, unmutated IGHV genes)
showed hierarchical impact on OS (data not shown).
MDM2SNP309 genotype and disease characteristics
There was no significant difference in genotype distri-
bution among cohorts (P=0.11). Furthermore, the
MDM2SNP309 was not associated with particular disease
characteristics, such as age of onset, 17p-, 11q-, +12q, or
IGHV gene mutation status (Table 3). To assess the poten-
tial influence of the genotype on the patients' prognosis,
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Figure 1. Summary of individual studies as reported.
Study level data (s=12)
Individual studies (s=10)
Individual patient data
(n=2595)
Patient data excluded
(n=3) 
Studies excluded (s=2)
Lahiri et al.21 (n=83)
Malek et al.22 (n=87) 
we analyzed TFT and OS using an additive genetic model.
Results of the analyses of OS in individual cohorts and the
summarizing IPD meta-analysis are illustrated by the for-
est plot shown in Figure 2. The funnel plot of individual
studies was roughly symmetrical, indicating no evidence
of publication bias in this study (Figure 3). Results for TFT
were comparable. To account for heterogeneity, meta-
analysis was carried out stratified for study cohorts.
Table 1. Comparison of clinical and biological characteristics between the ten study cohorts.
Factor Overall Brno Essen Heidelberg Leicester Linkoping Novara Salzburg Uppsala Ulm Bournemouth P
(n=2598) (n=164) (n=166) (n=225) (n=402) (n=210) (n=331) (n=140) (n=418) (n=242) (n=300) 
Age < 0.001 
Median 63 58.6 61.0 60.9 65.0 62.6 68.2 61.8 64.6 56.8 65.6 
Range 20.9 - 96.6 32.1 - 79.4 30.0 - 93.0 29.9 - 85.6 33.5 - 96.6 38.3 - 87.0 20.9 - 92.4 36.7 - 85.9 32.6 - 88.3 25.4 - 79.6 37.1 - 93.3 
n.a. 43 15 1 1 26 
Sex 0.001 
Female 939 (36.2%) 61 (37.2%) 53 (31.9%) 90 (40.0%) 136 (33.8%) 64 (30.5%) 156 (47.1%) 51 (36.4%) 142 (34.0%) 77 (31.8%) 109 (36.7%) 
Male 1656 (63.8%) 103 (62.8%) 113 (68.1%) 135 (60.0%) 266 (66.2%) 146 (69.5%) 175 (52.9%) 89 (63.6%) 276 (66.0%) 165 (68.2%) 188 (63.3%) 
n.a. 3 3 
Binet stage < 0.001 
A 1392 (68.3%) 123 (77.8%) 117 (70.5%) 151 (74.0%) 108 (56.2%) 101 (52.3%) 256 (77.3%) 254 (73.2%) 141 (69.8%) 141 (57.6%) 
B 400 (19.6%) 13 (8.2%) 36 (21.7%) 41 (20.1%) 56 (29.2%) 41 (21.2%) 41 (12.4%) 66 (19.0%) 46 (22.8%) 60 (24.5%) 
C 246 (12.1%) 22 (13.9%) 13 (7.8%) 12 (5.9%) 28 (14.6%) 51 (26.4%) 34 (10.3%) 27 (7.8%) 15 (7.4%) 44 (18.0%) 
n.a. 560 6 21 210 17 140 71 40 55 
IGHV gene
mutation status < 0.001 
Mutated 1345 (55.1%) 57 (35.8%) 51 (50.0%) 99 (45.0%) 276 (69.5%) 56 (31.8%) 201 (61.7%) 83 (65.9%) 241 (58.8%) 104 (46.0%) 177 (59.0%) 
Unmutated 1097 (44.9%) 102 (64.2%) 51 (50.0%) 121 (55.0%) 121 (30.5%) 120 (68.2%) 125 (38.3%) 43 (34.1%) 169 (41.2%) 122 (54.0%) 123 (41.0%) 
n.a. 156 5 64 5 5 34 5 14 8 16 
del 17p13 < 0.001 
no 1967 (93%) 149 (90.9%) 130 (92.9%) 217 (96.4%) 266 (95.0%) 286 (89.4%) 118 (84.3%) 308 (93.3%) 227 (93.8%) 266 (96.7%) 
yes 149 (7%) 15 (9.1%) 10 (7.1%) 8 (3.6%) 14 (5.0%) 34 (10.6%) 22 (15.7%) 22 (6.7%) 15 (6.2%) 9 (3.3%) 
n.a. 482 26 122 210 11 88 25 
del 11q22.q23 < 0.001 
no 1817 (87.6%) 130 (79.3%) 128 (91.4%) 193 (85.8%) 241 (86.1%) 297 (92.8%) 92 (97.9%) 286 (86.7%) 203 (83.9%) 247 (88.5%) 
yes 257 (12.4%) 34 (20.7%) 12 (8.6%) 32 (14.2%) 39 (13.9%) 23 (7.2%) 2 (2.1%) 44 (13.3%) 39 (16.1%) 32 (11.5%) 
n.a. 524 26 122 210 11 46 88 21 
trisomy 12q13 0.002 
no 1715 (83.2%) 137 (84.0%) 124 (88.6%) 180 (80.0%) 227 (81.1%) 257 (80.3%) 79 (84.0%) 291 (88.2%) 213 (88.0%) 207 (77.2%) 
yes 347 (16.8%) 26 (16.0%) 16 (11.4%) 45 (20.0%) 53 (18.9%) 63 (19.7%) 15 (16.0%) 39 (11.8%) 29 (12.0%) 61 (22.8%) 
n.a. 536 1 26 0 122 210 11 46 88 0 32 
MDM2 SNP309 0.11 
genotype 
GG 318 (12.2%) 27 (16.5%) 26 (15.7%) 23 (10.2%) 43 (10.7%) 17 (8.1%) 49 (14.8%) 20 (14.3%) 43 (10.3%) 31 (12.8%) 39 (13.0%) 
TG 1195 (46%) 82 (50.0%) 77 (46.4%) 111 (49.3%) 175 (43.6%) 98 (46.7%) 159 (48.0%) 58 (41.4%) 190 (45.5%) 119 (49.2%) 126 (42.0%) 
TT 1084 (41.7%) 55 (33.5%) 63 (38.0%) 91 (40.4%) 183 (45.6%) 95 (45.2%) 123 (37.2%) 62 (44.3%) 185 (44.3%) 92 (38.0%) 135 (45.0%) 
n.a. 1 1 
Table 2. Comparison of time-to-event characteristics between the ten study cohorts.
Overall Brno Essen Heidelberg Leicester Linkoping Novara Salzburg Uppsala Ulm Bournemouth P
(n=2598) (n=164) (n=166) (n=225) (n=402) (n=210) (n=331) (n=140) (n=418) (n=242) (n=300) 
Follow-up 
Median 97.3 89.8 61 68.5 79.8 106.6 73.9 67 117.3 56.9 145.3 
n.a. 7 5 2 
Overall survival < 0.001
Median 143.5 135.5 297 104.2 184.2 112.6 156.6 207 114.9 300.9 132.5 
CI95 135 - 153.8 114.6 - Inf. 199 - Inf. 97.9 - 132.8 163.4 - 228.3 92.9 - 143.5 137 - Inf. 165 - Inf. 106.2 - 125.7 170.6 - Inf. 117.1 - 157 
n.a. 7 5 2 
Time to first treatment < 0.001 
Median 44.9 42.7 82 50.1 18.2 20.7 77.3 74 47 40 44.6 
CI95 41.6 - 48.4 34 - 54 52 - 119 43.5 - 63 11.3 - 25.5 14 - 27.6 55.5 - 99.2 62 - 106.1 26.7 - 66.7 31.6 - 55.1 34 - 60.4 
n.a. 367 245 7 105 10 
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Stratified log rank tests showed no significant differences
based on the polymorphism with respect to OS and TFT
(P=0.76 and P=0.58, respectively). Specifically, the GG
genotype group had a cohort-adjusted median OS of 151
months compared to 153 months for the TG genotype
group and 149 months for the TT genotype group (Figure
4). Cohort-adjusted median TFT was 43 months for the
GG genotype group, and 42 months for the TG and the
TT genotype group. 
Because of the known interaction of MDM2 with the
p53 pathway, we also assessed the impact of the SNP in
the group with and the group without 17p deletion. In the
subset of patients without 17p deletion, the survival dis-
tribution in the sets defined by the three genotypes were
comparable (stratified log rank test: P=0.58). Accordingly,
no statistically significant impact of the genotype could
be demonstrated in the subset with 17p deletion (strati-
fied log rank test: P=0.56). Similar results were obtained
for TFT.
Multivariable meta-analysis
We performed a cohort-stratified Cox proportional haz-
ards regression analysis to assess the impact of the MDM2
genotype on overall and treatment-free survival consider-
ing known prognostic factors. The first model included
MDM2 genotype, sex, age and IGHV gene mutation sta-
tus as well as the stratification according to cohorts. As
shown in Table 4, advanced age, male sex and unmutated
IGHV genes were significantly associated with inferior
survival but not the MDM2 genotype (P=0.31). Results for
TFT were comparable.
In a separate model, we included cytogenetic aberra-
A. Benner et al.
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Table 3. Association of the MDM2SNP309 genotype and patients’ characteristics. 
Factor Overall GG TG TT P
Age 0.68 
Median 63 63.9 62.6 63.4 
Range 20.9 - 96.6 31.0 - 88.3 25.4 - 96.6 20.9 - 93.0 
n.a. 43 4 26 15 
Sex 0.68 
F 939 (36.2%) 114 (35.8%) 442 (37.0%) 382 (35.3%) 
M 1656 (63.8%) 204 (64.2%) 751 (63.0%) 701 (64.7%) 
n.a. 3 0 2 1 
Binet stage 0.50 
A 1392 (68.3%) 172 (66.7%) 649 (68.2%) 571 (69.0%) 
B 400 (19.6%) 60 (23.3%) 182 (19.1%) 158 (19.1%) 
C 246 (12.1%) 26 (10.1%) 121 (12.7%) 99 (12.0%) 
n.a. 560 60 243 256 
IGHV gene status 0.53 
Mutated 1345 (55.1%) 159 (52.1%) 617 (55.2%) 569 (55.8%) 
Unmutated 1097 (44.9%) 146 (47.9%) 500 (44.8%) 451 (44.2%) 
n.a. 156 13 78 64 
del 17p13 0.91 
no 1967 (93%) 252 (92.3%) 917 (93.0%) 798 (93.1%) 
yes 149 (7%) 21 (7.7%) 69 (7.0%) 59 (6.9%) 
n.a. 482 45 209 227 
del 11q22.q23 0.64 
no 1817 (87.6%) 237 (89.1%) 841 (87.0%) 739 (87.9%) 
yes 257 (12.4%) 29 (10.9%) 126 (13.0%) 102 (12.1%) 
n.a. 524 52 228 243 
trisomy 12q13 0.17 
no 1715 (83.2%) 221 (84.0%) 815 (84.5%) 679 (81.3%) 
yes 347 (16.8%) 42 (16.0%) 149 (15.5%) 156 (18.7%) 
n.a. 536 55 231 249 
Figure 2. Forest plot of the IPD-based meta-analysis for overall survival. The plot shows the individual results of univariable Cox regression
models for each study cohort together with the meta-analysis result with respect to the MDM2SNP309 genotype using an additive genetic model.
The estimated hazard ratios, HR, together with their 95% confidence intervals are shown numerically and graphically. In addition the numbers
of events, D, and observations, N, as well as the proportions of the three genotypes are provided. The results of individual studies are shown
as squares centered on each cohort's point estimate of the hazard ratio (HR). Size of a square represents the precision of the estimate (the
inverse of the squared standard error). 95% confidence intervals are represented by horizontal lines. The overall HR estimate from the IPD
meta-analysis and its confidence interval are shown at the bottom, represented by a diamond. Testing heterogeneity resulted in Q(df=9) =
14.9, P = 0.10, with I2 =39%.
Hazard Ratio
0.2 1.0 2.0 3.0 4.0  5.0
Study D/N TT TG GG HR (95% CI)
IPD 858/2405 1.05 (0.95, 1.16)
Brno 50/159 0.34 0.50 0.16 1.82 (0.85, 3.89)
Essen 9/98 0.38 0.46 0.16 0.84 (0.10, 7.28)
Heidelberg 72/220 0.40 0.49 0.10 1.43 (0.67, 3.04)
Leicester 107/393 0.46 0.44 0.11 0.81 (0.42, 1.55)
Linkoping 86/176 0.45 0.47 0.08 1.66 (0.84, 3.28)
Novara 86/325 0.37 0.48 0.15 1.01 (0.54, 1.88)
Salzburg 24/126 0.44 0.41 0.14 4.30 (1.37, 13.47)
Uppsala 231/140 0.44 0.45 0.10 1.16 (0.79, 1.69)
Ulm 33/226 0.38 0.49 0.13 0.63 (0.20, 1.97)
Bournemouth 160/272 0.45 0.42 0.13 0.70 (0.45, 1.10)
tions (17p-, 11q-, +12q). In this model, sex, age, IGHV
gene mutation status, and cytogenetic aberrations were
associated with increased risk of death. Again, the
MDM2SNP309 genotype was not significantly associated
with overall survival (P=0.28; Table 4). Considering treat-
ment-free survival, age (P=0.10) and the MDM2SNP309 geno-
type (P=0.85) were the only factors that were not statisti-
cally significant.
Discussion
The current study used individual patient data to assess
the role of a particular host genetic factor in CLL. In con-
trast to other large studies, we focused on the prognostic
impact of the MDM2 polymorphism. The size of the
cohort allowed us to perform subgroup analysis with suf-
ficient statistical power to account for the biological het-
erogeneity of CLL. 
In response to cellular stress, the p53 protein is stabi-
lized and regulates the activity of key effectors of cellular
processes, such as DNA repair, cell-cycle arrest, senes-
cence, and apoptosis. These p53-mediated responses are
crucial both in reducing cancer frequency and in mediating
the response of commonly used cancer therapies. Not sur-
prisingly, p53 loss or mutation leads to very poor outcome
in hematologic malignancies, and the impact is particular-
ly striking in CLL. There is a large body of evidence sug-
gesting that the p53 pathway harbors functional inherited
single-nucleotide polymorphisms (SNPs) that affect p53
signaling in cells, resulting in differences in cancer risk and
clinical outcome in humans (reviewed by Grochola et al.27).
Recent elegant work with mice carrying the MDM2SNP309G
allele showed that MDM2SNP309G/G cells exhibit elevated
mdm2 levels, reduced p53 levels, and decreased apoptosis
with the MDM2SNP309G allele potentiating the tumor pheno-
type, and altered the tumor spectrum in mice inheriting a
p53 hot-spot mutation.28 
Although the number of studies on the prognostic
impact of individual SNPs in cancer, including CLL, is rap-
idly increasing, the validation of the results obtained in
these studies is often disappointing. Meta-analysis has
become an essential part of the process of SNP evaluation.
In CLL, IPD-based meta-analysis have so far been limited
MDM2 promotor polymorphism and disease characteristics in CLL leukemia
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Figure 3. Contour-enhanced funnel plot of the OS analysis. The black
dots indicate the cohort-specific estimates of the log hazard ratio
and their standard errors; the vertical dashed line shows the summa-
ry estimate. Cohorts are indicated by the first two letters of their
names. The shaded regions reveal the P value in each study relating
to the test of the null hypothesis that the log (hazard ratio) is zero.
The funnel plot of the OS analyses with respect to MDM2SNP309 geno-
types is roughly symmetrical, indicating no evidence of publication
bias in this study.
Figure 4. Estimated distributions of overall survival. The solid lines
show the direct adjusted estimates of survival curves corresponding
to MDM2 genotype. Adjustment was made with respect to the differ-
ent cohorts of the study. Dashed lines represent the unadjusted
Kaplan-Meier estimates.
Table 4. Cox regression models for overall survival, stratified by study
center. Stratified Cox proportional hazards model including covariates
age, sex, IGHV mutation status and MDM2SNP309 (10 centers) and extend-
ed model, additionally including cytogenetic aberrations (17p-,11q- and
+12q; 9 centers).
Effect Hazard ratio 95% CI P
Age 10 years 1.94 1.80 - 2.09 < 0.001
Sex M:F 1.61 1.39 - 1.86 < 0.001
IGHV gene UM:M 3.18 2.74 - 3.68 < 0.001
mutation status 
MDM2SNP309 dG* 1.11 0.91 - 1.35 0.31
Effect Hazard ratio 95% CI P
Age 10 years 1.94 1.78 - 2.12 < 0.001
Sex M:F 1.58 1.32 - 1.88 < 0.001
IGHV gene UM:M 3.06 2.55 - 3.68 < 0.001
mutation status 
17p13- yes:no 3.14 2.45 - 4.03 < 0.001
11qq23- yes:no 1.48 1.19 - 1.84 < 0.001
+12q13 yes:no 1.44 1.19 - 1.76 < 0.001
MDM2SNP309 dG* 1.14 0.90 - 1.45 0.28
*dG: additional copy of G allele.
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to clinical trial analysis focusing on clinical questions such
as early versus late treatment,29 immunoglobulin prophy-
laxis30 or response to treatment.31,32 This is, therefore, the
first IPD based meta-analysis in which the clinical and
prognostic significance of a biomarker such as MDM2
gene polymorphism is evaluated. To that purpose, we
have compiled a unique data set of 2598 patients from 10
centers using IPD-based meta-analysis to analyze the
association between MDM2SNP309 polymorphism, genetic
and clinical features and clinical outcome in CLL. We
observed a strong heterogeneity in the cohorts studied,
likely to be due to referral patterns and health care differ-
ences across countries. The incidence of the MDM2SNP309
genotype in different studies argues for comparability of
the different techniques used to detect it.
In contrast to single center studies, we did not find a cor-
relation between MDM2SNP309, disease characteristics and
outcome, including patients’ age at diagnosis, genetic
lesions, IGHV mutations, TFT or overall survival. On the
other hand, the current study provides a unique dataset to
estimate the impact of genetic aberrations and IGHV
mutational status for outcome of patients with CLL. There
are additional smaller studies that we have not been able
to include in the analysis for various reasons;21-23,33 based
on the limited number of cases involved the omission is
unlikely to affect the results.
In our analysis, we have used an additive genetic model
considering the number of copies of the variant G allele and
stratification by study cohort. We have also analyzed the
data using mixed effects Cox models with random cohort
effect providing comparable results (data not shown). One
shortcoming of our study is the lack of data on TP53 muta-
tions, which are now accepted as markers of poor prognosis
in CLL but which were not widely available when the
series analyzed here were investigated. The analysis within
the group of patients with 17p deletion did not show an
impact of the MDM2SNP309 suggesting that, in CLL, interac-
tion with p53 status is unlikely. While no sample exchange
and validation experiments were performed, the incidence
of the SNP allele distribution was similar across centers sug-
gesting that technology reproducibility was not a confound-
ing factor. While comprehensive data on the mRNA or
Protein expression of mdm2 in CLL are missing, a larger
study detected no impact of the MDM2SNP309 on mRNA lev-
els.11 Based on our data, further meta-analyses are encour-
aged; this will help classify and develop the hierarchy of rel-
evant prognostic factors in this disease. This is particularly
important as, with the identification of novel mutations
(e.g. SF3B1, NOTCH1, BIRC3, ATM, MYD88), the number
of prognostic factors has increased, necessitating large
cohorts to avoid over-fitted models. 
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